Prevention of drug carryover effects in studies assessing antimycobacterial efficacy of TMC207

Journal of Clinical Microbiology

Volumn 46, Issue 7, 2008, Pages 2212-2215

  Lounis, Nacer ^a,c   Gevers, Tom ^a   Van Den Berg, Joke ^a   Verhaeghe, Tom ^b   Van Heeswijk, Rolf ^a   Andries, Koen ^a  

^a TIBOTEC BVBA   (Belgium)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c BVBA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

1 (6 BROMO 2 METHOXY 3 QUINOLINYL) 4 DIMETHYLAMINO 2 (1 NAPHTHYL) 1 PHENYL 2 BUTANOL; ANTIMYCOBACTERIAL AGENT; BOVINE SERUM ALBUMIN; 1 (6 BROMO 2 METHOXY QUINOLIN 3 YL) 4 DIMETHYLAMINO 2 (3 FLUOROPHENYL) 1 PHENYL BUTAN 2 OL; 1-(6-BROMO-2-METHOXY-QUINOLIN-3-YL)-4-DIMETHYLAMINO-2-(3-FLUOROPHENYL)-1-PHENYL-BUTAN-2-OL; QUINOLINE DERIVATIVE; TUBERCULOSTATIC AGENT;

AGAR MEDIUM; ARTICLE; CULTURE MEDIUM; DRUG EFFICACY; HUMAN; IN VITRO STUDY; INOCULATION; LOEWENSTEIN MEDIUM; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MYCOBACTERIUM; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; SPUTUM; ANIMAL; CHEMISTRY; DRUG EFFECT; METHODOLOGY; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; TUBERCULOSIS;

BACTERIA (MICROORGANISMS); BOVINAE; MYCOBACTERIUM TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; BACTERIOLOGICAL TECHNIQUES; CULTURE MEDIA; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; QUINOLINES; TUBERCULOSIS;

EID: 49049106807     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.00177-08     Document Type: Article

References (10)

1. Andries, K., P. Verhasselt, J. Guillemont, H. W. H. Göhlmann, J. M. Neefs, H. Winkler, J. V. Gestel, P. Timmerman, M. Zhu, E. Lee, P. Williams, D. D. E. Chaffoy, E. Huitric, S. Hoffner, E. Cambau, C. Truffot-Pernot, N. Lounis, and V. Jarlier. 2005. R207910, a diarylquinoline active on ATP synthase of Mycobacterium tuberculosis. Science 307:223-227.
2. Gruet, P., C. Gaillard, B. Boisrame, D. Duffaut, A. M. Grimoud, and G. Camy. 1995. Use of an oral antiseptic bioadhesive tablet in dogs. J. Vet. Dent. 12:87-91.
3. Ishida, K., P. A. Guze, G. M. Kalmanson, K. Albrandt, and L. B. Guze. 1982. Variables in demonstrating methicillin tolerance in Staphylococcus aureus strains. Antimicrob. Agents Chemother. 21:688-690.
4. Ji, B., N. Lounis, C. Truffot-Pernot, and J. Grosset. 1994. Effectiveness of various antimicrobial agents against Mycobacterium avium complex in the beige mouse model. Antimicrob. Agents Chemother. 38:2521-2529.
5. Lenaerts, A. J., D. Hoffi, S. Aly, S. Ehlers, K. Andries, L. Cantarero, I. M. Orme, and R. J. Basaraba. 2007. Location of persisting mycobacteria in a guinea pig model of tuberculosis revealed by R207910. Antimicrob. Agents Chemother. 51:3338-3345.
6. Lounis, N., N. Veziris, A. Chauffour, C. Truffot-Pernot, K. Andries, and V. Jarlier. 2006. Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration. Antimicrob. Agents Chemother. 50:3543-3547.
7. Perronne, C. M., R. Malinverni, and M. Glauser. 1987. Treatment of Staphylococcus aureus endocarditis in rats with coumermycin A1 and ciprofloxacin, alone or in combination. Antimicrob. Agents Chemother. 31:539-543.
8. Portero, J. L., and M. Rubio. 2007. New anti-tuberculosis therapies. Expert Opin. Ther. Patents 17:617-637.
9. R. Rustomjee, A. H. Diacon, J. Allen, A. Venter, C. Reddy, R. F. Patientia, T. C. P. Mthiyane, T. De Marez, R. van Heeswijk, R. Kerstens, A. Koul, K. De Beule, P. R. Donald, and D. F. McNeeley. Early bactericidal activity and pharcokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob. Agents Chemother., in press.
10. Sheikh, W. 1981. Development and validation of a neutralizer system for in vitro evaluation of some antiseptics. Antimicrob. Agents Chemother. 19:429-434.